Targeting dopamine pathways with hybrid molecules: Emerging outlook for cancer treatment.
2/5 보강
TL;DR
This review synthesizes current advances in DA-pathway-targeting hybrid constructs, explores their mechanistic rationale, and highlights the major biological and translational challenges that must be addressed to support their development.
OpenAlex 토픽 ·
Cancer, Stress, Anesthesia, and Immune Response
Nerve injury and regeneration
Neuropeptides and Animal Physiology
This review synthesizes current advances in DA-pathway-targeting hybrid constructs, explores their mechanistic rationale, and highlights the major biological and translational challenges that must be
APA
Piotr Koch, Natalia Pielaszkiewicz, et al. (2026). Targeting dopamine pathways with hybrid molecules: Emerging outlook for cancer treatment.. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 222, 115031. https://doi.org/10.1016/j.ejpb.2026.115031
MLA
Piotr Koch, et al.. "Targeting dopamine pathways with hybrid molecules: Emerging outlook for cancer treatment.." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, vol. 222, 2026, pp. 115031.
PMID
41724450 ↗
Abstract 한글 요약
Dopamine (DA)-related signaling has increasingly been recognized as a contributor to cellular regulation, affecting pathways associated with growth, survival, and receptor-mediated signaling. This understanding has motivated the development of hybrid therapeutic platforms that combine dopaminergic modulation with additional strategies, such as receptor co-targeting and selective drug delivery. These systems encompass diverse molecular formats, including multifunctional peptide chimeras acting on dopaminergic and somatostatin receptors, as well as DA-functionalized nanomaterials or polymeric conjugates. Collectively, these hybrids demonstrate the potential for enhanced pharmacologic precision, improved intracellular accumulation, and reduced off-target effects as compared to those of conventional compounds. Despite promising preclinical evidence, multiple barriers remain before these technologies can be translated clinically. This review synthesizes current advances in DA-pathway-targeting hybrid constructs, explores their mechanistic rationale, and highlights the major biological and translational challenges that must be addressed to support their development.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.